Showing results (71-80 of 158) with videos related to

Sort By:
Pageof 16
Annals of the Rheumatic Diseases|May 17, 2022
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trialsIan N Bruce, Richard A Furie, Eric F Morand, et al.
The Journal of Rheumatology|May 23, 2007
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosusF Yesim K Demirci, Susan Manzi, Rosalind Ramsey-Goldman, et al.
Arthritis and Rheumatism|February 1, 2006
Platelet C4d is highly specific for systemic lupus erythematosusJeannine S Navratil, Susan Manzi, Amy H Kao, et al.
The American Journal of Cardiology|September 9, 2008
C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritisAmy H Kao, Mary Chester M Wasko, Shanthi Krishnaswami, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP-SC StudySusan Manzi, Ian N Bruce, Eric F Morand, et al.
Stroke|October 18, 2008
Platelet C4d is associated with acute ischemic stroke and stroke severityNidhi Mehta, Ken Uchino, Saeed Fakhran, et al.
The Lancet. Rheumatology|January 17, 2024
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialRichard A Furie, Eric F Morand, Ian N Bruce, et al.
The Journal of Rheumatology|May 23, 2002
The rate and pattern of organ damage in late onset systemic lupus erythematosusPeter Maddison, Vernon Farewell, David Isenberg, et al.
Pageof 16